US Criminal Probe into Abbott Infant-Formula Plant Closed

Abbott Laboratories (ABT) has reached a proposed settlement with US authorities to resolve a criminal investigation into its infant formula plant. The settlement involves civil penalties under the False Claims Act, with the amount undisclosed.

Details of the Action

The criminal probe began after reports of potential regulatory violations at Abbott's infant formula facility. The proposed settlement closes the case without criminal charges.

Company's Stance

Abbott reiterated its commitment to product safety and quality, viewing the settlement as a positive step to end legal uncertainty. It did not comment on penalty specifics.

Precedents and Context

This case follows increased regulatory scrutiny on the infant formula industry after the 2022 shortage crisis. Abbott previously closed a Michigan plant due to safety concerns.

Potential Financial Impact

The settlement amount has not been disclosed but is expected to be within typical civil penalty ranges under the False Claims Act. It may affect next quarter's earnings but removes legal overhang.